LBX PHARMACY CHAIN JSC operates in the Drug stores and proprietary stores sector.
In addition to historical fundamental analyses, the complete report available to purchase compares LBX PHARMACY CHAIN JSC with three other
companies in this sector in China:
HPGC Renmintongtai Pharmaceutical Corp
sales of 8.01 billion Chinese Renmimbi [US$1.17 billion]
of which 99%
was Pharmaceutical Commerce),
Dashenlin Pharmaceutical Group Co Ltd
(7.42 billion Chinese Renmimbi [US$1.08 billion]
of which 97%
was Pharmaceutical retail), and
Yunnan Hongxiang Yixintang Pharmaceutical Co Ltd
(7.75 billion Chinese Renmimbi [US$1.13 billion]
of which 94%
was Retail Sale).
LBX PHARMACY CHAIN JSC reported sales of 7.50 billion Chinese Renmimbi (US$1.09 billion)
December of 2017.
increase of 23.1%
versus 2016, when the company's sales were 6.09 billion Chinese Renmimbi.
Sales at LBX PHARMACY CHAIN JSC have increased during each of the previous five years
(and since 2012, sales have increased a total of 164%).
Sales of Pharmaceutical Wholesale saw an increase
that was more than double the company's growth rate: sales were up
93.1% in 2017, from
291.68 million Chinese Renmimbi to 563.32 million Chinese Renmimbi.